James Rucker
Senior Clinical Lecturer at King's College London
Data updated
Research Footprint
James Rucker appears in 28 tracked papers (2016–2026), most studied alongside Psilocybin, 5-MeO-DMT and LSD, across Depressive Disorders, Safety & Risk Management and Anxiety Disorders.
Most-cited paper: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (1520 citations).
Frequent co-authors: Allan Young, Mathieu Seynaeve and Fiona Dunbar.
Publication Landscape
How the 28 papers Blossom tracks for James Rucker line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has James Rucker's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 28 of 28 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does James Rucker publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does James Rucker publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
James Rucker is a consultant psychiatrist and leading trialist in the UK. He heads the Psychedelic Trials Group at the Institute of Psychiatry, Psychology & Neuroscience, where he conducts clinical trials on psilocybin, MDMA, and ketamine. His work focuses on integrating these pharmacological breakthroughs with psychotherapeutic frameworks for psychiatric recovery.
Key Impact
Leads the Psychedelic Trials Group investigating psilocybin for treatment-resistant depression.
Collaboration Network
49 collaborators· click a node to visit their profile
Full network →Collaboration Network
See James Rucker's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations James Rucker is associated with.